Drugs / Afimkibart
Afimkibart
Trials 20
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT07665723 | Jun 2026 → Jul 2027 expected | ulcerative colitis | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 1 | NCT06903065 | Apr 2025 → Sep 2026 overdue | — | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05107492 | Nov 2021 → Apr 2022 | inflammatory bowel disease | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04269538 | Feb → Nov 2020 | — | Telavant, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01989143 | Dec 2013 → Mar 2015 | — | Telavant, Inc. | Completed | No outcome recorded |
| Phase 28 trials · 1 missed | ||||||
| Phase 2 | NCT07620392 | Jun 2026 → Jul 2033 expected | rheumatoid arthritis | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 2 | NCT07223697 | Jan 2026 → Mar 2033 expected | atopic eczema | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 2 | NCT07137598 | Dec 2025 → Apr 2027 expected | rheumatoid arthritis | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 2 | NCT06863961 | Apr 2025 → Jul 2026 overdue | atopic eczema | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05471492 | Jul 2023 → Aug 2026 | Crohn disease | Telavant, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT05910528 | Jul 2023 → Dec 2026 expected | Crohn disease | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04090411 | Dec 2019 → Oct 2022 | ulcerative colitis | Hoffmann-La Roche | Completed | Missed primary |
| Phase 2 | NCT02840721 | Oct 2016 → May 2018 | ulcerative colitis | Telavant, Inc. | Completed | No outcome recorded |
| Phase 37 trials | ||||||
| Phase 3 | NCT07846683 | Nov 2026 → May 2028 expected | ulcerative colitis | Hoffmann-La Roche | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07298421 | Aug 2026 → May 2030 expected | inflammatory bowel disease | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 3 | NCT07158242 | Apr 2026 → Mar 2030 expected | ulcerative colitis | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 3 | NCT06819891 | May 2025 → Dec 2028 expected | inflammatory bowel disease | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 3 | NCT06819878 | Mar 2025 → Dec 2028 expected | inflammatory bowel disease | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 3 | NCT06588855 | Dec 2024 → Oct 2026 expected | ulcerative colitis | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06589986 | Sep 2024 → Jan 2027 expected | ulcerative colitis | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 22 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Afimkibart | “We evaluated the safety and efficacy of multiple doses of afimkibart, a TL1A-directed antibody, in patients with moderately-to-severely active ulcerative colitis.” PMID 40706613 ↗ Jul 2025 |
| Known as | PF-06480605 | “A PHASE 1, RANDOMIZED, DOUBLE-BLIND, THIRD-PARTY OPEN, PLACEBO-CONTROLLED STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY FOLLOWING SINGLE SUBCUTANEOUS DOSE OF...” NCT05107492 ↗ |
| Known as | RO7790121 | “The purpose of this study is to assess the efficacy and safety of Afimkibart (also known as RO7790121) in participants with moderate to severe atopic dermatitis (AD).” NCT06863961 ↗ |
| Modality | Monoclonal antibody | “PF-06480605, a fully human immunoglobulin G1 monoclonal antibody, targets TL1A.” PMID 31758576 ↗ Jan 2020 |
| Route | Intravenous | “intravenous (IV) and subcutaneous (SC) PF-06480605” PMID 31758576 ↗ Jan 2020 |
| Route | Subcutaneous | “intravenous (IV) and subcutaneous (SC) PF-06480605” PMID 31758576 ↗ Jan 2020 |